Cargando…
Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
Reducing the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is the key ultimate goal set in essentially all treatment guidelines. There has been solid evidence supporting the relationship between serum hepatitis B virus (HBV) DNA level and risk of HCC. Antivir...
Autores principales: | Yip, Terry Cheuk-Fung, Lai, Jimmy Che-To, Wong, Grace Lai-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567686/ https://www.ncbi.nlm.nih.gov/pubmed/32974760 http://dx.doi.org/10.1007/s00535-020-01726-3 |
Ejemplares similares
-
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021) -
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015) -
Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015) -
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011) -
Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular
carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020)